https://www.prognyx.com/blog/j-j-s-rybrevant-faspro-posts-77-response-rate-in-first-line-head-and-neck-cancerPrognyxen2026-10-29J J's RYBREVANT FASPRO posts 77% response rate in first-line head and neck cancer https://www.prognyx.com/blog/merck-s-pembrolizumab-cuts-progression-risk-43-in-dmmr-endometrial-cancerPrognyxen2026-10-28Merck's pembrolizumab cuts progression risk 43% in dMMR endometrial cancer https://www.prognyx.com/blog/fda-approves-pfizer-s-talazoparib-enzalutamide-for-hrr-mutant-prostate-cancerPrognyxen2026-10-27FDA approves Pfizer's talazoparib-enzalutamide for HRR-mutant prostate cancer